Sodium metavanadate

Names

[ Name ]:
Sodium metavanadate

[Synonym ]:
Vanadicacidsodiumsalt
Sodium metavanadate
Vanadate,sodium
Vanadium, olatodioxo-, sodium salt (1:1)
SODIUM MONOVANADATE
EINECS 237-272-7
Sodium (meta)vanadate
Sodium oxido(dioxo)vanadium
MFCD00011125
Natriummetavanadat
metawanadansodowy
sodium vanadium oxide
SODIUM VANADATE
SODIUM M-VANADATE

Chemical & Physical Properties

[ Melting Point ]:
600 °C

[ Molecular Formula ]:
NaO₃V

[ Molecular Weight ]:
121.929

[ Exact Mass ]:
121.918480

[ PSA ]:
57.20000

[ Stability ]:
Stable.

MSDS

Click to get detail MSDS

Toxicological Information

CHEMICAL IDENTIFICATION

RTECS NUMBER :: YW1050000

CHEMICAL NAME :: Vanadic acid, monosodium salt

CAS REGISTRY NUMBER :: 13718-26-8

LAST UPDATED :: 199710

DATA ITEMS CITED :: 45

MOLECULAR FORMULA :: O3-V.Na

MOLECULAR WEIGHT :: 121.93

WISWESSER LINE NOTATION :: NA VA-O3

HEALTH HAZARD DATA

ACUTE TOXICITY DATA

TYPE OF TEST :: LD50 - Lethal dose, 50 percent kill

ROUTE OF EXPOSURE :: Oral

SPECIES OBSERVED :: Rodent - rat

DOSE/DURATION :: 98 mg/kg

TOXIC EFFECTS :: Behavioral - ataxia Lungs, Thorax, or Respiration - dyspnea Gastrointestinal - hypermotility, diarrhea

TYPE OF TEST :: LD50 - Lethal dose, 50 percent kill

ROUTE OF EXPOSURE :: Intraperitoneal

SPECIES OBSERVED :: Rodent - rat

DOSE/DURATION :: 12 mg/kg

TOXIC EFFECTS :: Details of toxic effects not reported other than lethal dose value

TYPE OF TEST :: LD50 - Lethal dose, 50 percent kill

ROUTE OF EXPOSURE :: Oral

SPECIES OBSERVED :: Rodent - mouse

DOSE/DURATION :: 74600 ug/kg

TOXIC EFFECTS :: Behavioral - ataxia Lungs, Thorax, or Respiration - dyspnea Gastrointestinal - hypermotility, diarrhea

TYPE OF TEST :: LD50 - Lethal dose, 50 percent kill

ROUTE OF EXPOSURE :: Intraperitoneal

SPECIES OBSERVED :: Rodent - mouse

DOSE/DURATION :: 36 mg/kg

TOXIC EFFECTS :: Behavioral - ataxia Lungs, Thorax, or Respiration - dyspnea Gastrointestinal - hypermotility, diarrhea

TYPE OF TEST :: LDLo - Lowest published lethal dose

ROUTE OF EXPOSURE :: Subcutaneous

SPECIES OBSERVED :: Mammal - dog

DOSE/DURATION :: 17 mg/kg

TOXIC EFFECTS :: Details of toxic effects not reported other than lethal dose value

TYPE OF TEST :: LDLo - Lowest published lethal dose

ROUTE OF EXPOSURE :: Intravenous

SPECIES OBSERVED :: Mammal - dog

DOSE/DURATION :: 11 mg/kg

TOXIC EFFECTS :: Details of toxic effects not reported other than lethal dose value

TYPE OF TEST :: LD50 - Lethal dose, 50 percent kill

ROUTE OF EXPOSURE :: Intravenous

SPECIES OBSERVED :: Mammal - cat

DOSE/DURATION :: 7180 ug/kg

TOXIC EFFECTS :: Vascular - BP elevation not characterized in autonomic section Vascular - BP lowering not characterized in autonomic section

TYPE OF TEST :: LDLo - Lowest published lethal dose

ROUTE OF EXPOSURE :: Oral

SPECIES OBSERVED :: Rodent - rabbit

DOSE/DURATION :: 200 mg/kg

TOXIC EFFECTS :: Details of toxic effects not reported other than lethal dose value

TYPE OF TEST :: LDLo - Lowest published lethal dose

ROUTE OF EXPOSURE :: Intravenous

SPECIES OBSERVED :: Rodent - rabbit

DOSE/DURATION :: 17 mg/kg

TOXIC EFFECTS :: Details of toxic effects not reported other than lethal dose value

TYPE OF TEST :: TDLo - Lowest published toxic dose

ROUTE OF EXPOSURE :: Oral

SPECIES OBSERVED :: Rodent - rat

DOSE/DURATION :: 25851 ug/kg/6W-I

TOXIC EFFECTS :: Gastrointestinal - malabsorption Kidney, Ureter, Bladder - changes in bladder weight Nutritional and Gross Metabolic - changes in calcium

TYPE OF TEST :: TDLo - Lowest published toxic dose

ROUTE OF EXPOSURE :: Oral

SPECIES OBSERVED :: Rodent - rat

DOSE/DURATION :: 517 mg/kg/12W-I

TOXIC EFFECTS :: Gastrointestinal - other changes Liver - other changes Nutritional and Gross Metabolic - changes in metals, not otherwise specified

TYPE OF TEST :: TDLo - Lowest published toxic dose

ROUTE OF EXPOSURE :: Oral

SPECIES OBSERVED :: Rodent - rat

DOSE/DURATION :: 3878 mg/kg/90D-I

TOXIC EFFECTS :: Cardiac - other changes Endocrine - other changes Biochemical - Neurotransmitters or modulators (putative) - catecholamine levels in CNS

TYPE OF TEST :: TDLo - Lowest published toxic dose

ROUTE OF EXPOSURE :: Oral

SPECIES OBSERVED :: Rodent - rat

DOSE/DURATION :: 718 mg/kg/30W-C

TOXIC EFFECTS :: Cardiac - pulse rate increase, without fall in BP Vascular - BP elevation not characterized in autonomic section Kidney, Ureter, Bladder - other changes in urine composition

TYPE OF TEST :: TDLo - Lowest published toxic dose

ROUTE OF EXPOSURE :: Intraperitoneal

SPECIES OBSERVED :: Rodent - rat

DOSE/DURATION :: 25 mg/kg/5D-I

TOXIC EFFECTS :: Brain and Coverings - other degenerative changes

TYPE OF TEST :: TDLo - Lowest published toxic dose

ROUTE OF EXPOSURE :: Intraperitoneal

SPECIES OBSERVED :: Rodent - rat

DOSE/DURATION :: 17500 ug/kg/10W-I

TOXIC EFFECTS :: Behavioral - changes in motor activity (specific assay) Gastrointestinal - decreased motility or constipation

TYPE OF TEST :: TDLo - Lowest published toxic dose

ROUTE OF EXPOSURE :: Oral

DOSE :: 1800 mg/kg

SEX/DURATION :: male 30 day(s) pre-mating

TOXIC EFFECTS :: Reproductive - Paternal Effects - testes, epididymis, sperm duct Reproductive - Fertility - male fertility index (e.g. # males impregnating females per # males exposed to fertile nonpregnant females)

TYPE OF TEST :: TDLo - Lowest published toxic dose

ROUTE OF EXPOSURE :: Intraperitoneal

DOSE :: 25 mg/kg

SEX/DURATION :: female 9 day(s) after conception

TOXIC EFFECTS :: Reproductive - Fertility - pre-implantation mortality (e.g. reduction in number of implants per female; total number of implants per corpora lutea) Reproductive - Fertility - post-implantation mortality (e.g. dead and/or resorbed implants per total number of implants) Reproductive - Specific Developmental Abnormalities - musculoskeletal system

TYPE OF TEST :: TDLo - Lowest published toxic dose

ROUTE OF EXPOSURE :: Intraperitoneal

DOSE :: 25 mg/kg

SEX/DURATION :: female 12 day(s) after conception

TOXIC EFFECTS :: Reproductive - Fertility - post-implantation mortality (e.g. dead and/or resorbed implants per total number of implants) Reproductive - Effects on Embryo or Fetus - fetotoxicity (except death, e.g., stunted fetus) Reproductive - Effects on Embryo or Fetus - fetal death

TYPE OF TEST :: TDLo - Lowest published toxic dose

ROUTE OF EXPOSURE :: Intraperitoneal

DOSE :: 40 mg/kg

SEX/DURATION :: female 6-15 day(s) after conception

TOXIC EFFECTS :: Reproductive - Fertility - post-implantation mortality (e.g. dead and/or resorbed implants per total number of implants) Reproductive - Effects on Embryo or Fetus - fetotoxicity (except death, e.g., stunted fetus) Reproductive - Effects on Embryo or Fetus - fetal death

TYPE OF TEST :: TDLo - Lowest published toxic dose

ROUTE OF EXPOSURE :: Intraperitoneal

DOSE :: 80 mg/kg

SEX/DURATION :: female 6-15 day(s) after conception

TOXIC EFFECTS :: Reproductive - Specific Developmental Abnormalities - craniofacial (including nose and tongue)

MUTATION DATA

TYPE OF TEST :: Sex chromosome loss and nondisjunction

TEST SYSTEM :: Human Lymphocyte

REFERENCE :: MUREAV Mutation Research. (Elsevier Science Pub. B.V., POB 211, 1000 AE Amsterdam, Netherlands) V.1- 1964- Volume(issue)/page/year: 319,205,1993 *** REVIEWS *** TOXICOLOGY REVIEW FRMBAZ Farmacia (Bucharest). (Rompresfilatelia, POB 12-201, Bucharest, Romania) V.1- 1953- Volume(issue)/page/year: 21,325,1973 TOXICOLOGY REVIEW 85DHAX "Medical and Biologic Effects of Environmental Pollutants Series," Washington, DC, National Academy of Sciences, 1972-77 Volume(issue)/page/year: V,46,1974 *** OCCUPATIONAL EXPOSURE LIMITS *** OEL-AUSTRALIA:TWA 0.05 mg(V2O5)/m3 JAN 1993 OEL-BELGIUM:TWA 0.05 mg(V2O5)/m3 JAN 1993 OEL-DENMARK:TWA 0.03 mg(V2O5)/m3 JAN 1993 OEL-FINLAND:TWA 0.5 mg(V2O5)/m3 JAN 1993 OEL-FRANCE:TWA 0.05 mg(V2O5)/m3 JAN 1993 OEL-GERMANY:TWA 0.05 mg(V2O5)/m3 JAN 1993 OEL-HUNGARY:TWA 0.05 mg(V2O5)/m3;STEL 0.1 mg(V205)/m3 JAN 1993 OEL-JAPAN:TWA 0.5 mg(V2O5)/m3 JAN 1993 OEL-THE NETHERLANDS:TWA 0.5 mg(V2O5)/m3 JAN 1993 OEL-THE PHILIPPINES:TWA 0.25 mg(V205)/m3 JAN 1993 OEL-POLAND:TWA 0.5 mg(V2O5)/m3 JAN 1993 OEL-SWEDEN:STEL 0.05 mg(V2O5)/m3 JAN 1993 OEL-SWEDEN:TWA 0.2 mg(V2O5)/m3 (dust) JAN 1993 OEL-SWITZERLAND:TWA 0.05 mg(V2O5)/m3;STEL 0.25 mg(V2O5)/m3 JAN 1993 OEL-TURKEY:TWA 0.5 mg(V2O5)/m3 JAN 1993 OEL-UNITED KINGDOM:TWA 0.05 mg(V2O5)/m3 (dust) JAN 1993 OEL-UNITED KINGDOM:TWA 0.5 mg(V2O5)/m3 JAN 1993 *** NIOSH STANDARDS DEVELOPMENT AND SURVEILLANCE DATA *** NIOSH RECOMMENDED EXPOSURE LEVEL (REL) : NIOSH REL TO VANADIUM (as V2O5), resp dust/fume-air:CL 0.05 mg/m3/15M REFERENCE : NIOSH* National Institute for Occupational Safety and Health, U.S. Dept. of Health, Education, and Welfare, Reports and Memoranda. Volume(issue)/page/year: DHHS #92-100,1992

Safety Information

[ Symbol ]:

GHS06, GHS08, GHS09

[ Signal Word ]:
Danger

[ Hazard Statements ]:
H301-H319-H332-H361fd-H372-H411

[ Precautionary Statements ]:
P201-P261-P273-P280-P301 + P310 + P330-P304 + P340 + P312

[ Personal Protective Equipment ]:
Eyeshields;Faceshields;Gloves;type P2 (EN 143) respirator cartridges

[ Hazard Codes ]:
T: Toxic;

[ Risk Phrases ]:
R25;R36/37/38

[ Safety Phrases ]:
S26-S36/37/39-S45

[ RIDADR ]:
UN 3285 6.1/PG 3

[ WGK Germany ]:
3

[ RTECS ]:
YW1050000

[ Packaging Group ]:
II

[ Hazard Class ]:
6.1

Articles

Alterations in brain neurotrophic and glial factors following early age chronic methylphenidate and cocaine administration.

Behav. Brain Res. 282 , 125-32, (2015)

Attention deficit hyperactivity disorder (ADHD) overdiagnosis and a pharmacological attempt to increase cognitive performance, are the major causes for the frequent (ab)use of psychostimulants in non-...

BDNF stimulation of protein synthesis in cortical neurons requires the MAP kinase-interacting kinase MNK1.

J. Neurosci. 35(3) , 972-84, (2015)

Although the MAP kinase-interacting kinases (MNKs) have been known for >15 years, their roles in the regulation of protein synthesis have remained obscure. Here, we explore the involvement of the MNKs...

Thymic Atrophy and Apoptosis of CD4+CD8+ Thymocytes in the Cuprizone Model of Multiple Sclerosis.

PLoS ONE 10 , e0129217, (2015)

Previous studies on the degenerative animal model of multiple sclerosis suggested that the copper-chelator cuprizone might directly suppress T-cell functions. Peripheral T-cell function in the cuprizo...

Related Compounds

The content on this webpage is sourced from various professional data sources. If you have any questions or concerns regarding the content, please feel free to contact service1@chemsrc.com.